Understanding Kidney Health in Youth with Diabetes and Obesity (PANTHER Study)

This observational study, called the PANTHER Study, is looking at how puberty affects kidney health in young people (ages 8-14) who have type 2 diabetes, pre-diabetes, or obesity. Researchers want to understand why kidney disease often starts early in life for these young people. You might be able to join if you have certain levels of HbA1c (a measure of blood sugar) or BMI (Body Mass Index), and do not have type 1 diabetes or existing kidney disease. The study uses diagnostic agents like Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, and Dextran 40 to measure how well your kidneys are working, specifically your effective renal plasma flow (ERPF) and glomerular filtration rate (GFR) over 3 hours. The study aims to enroll 100 participants.

Study design
This is an observational study, meaning researchers will observe participants without assigning specific treatments. It plans to enroll 100 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary measurements for kidney function (ERPF and GFR) are taken at 3 hours.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05008276

Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)

Recruiting
Not specifiedAges 8–14Observational
Petter Bjornstad
~100 participants
Updated 2025-03-24 on ClinicalTrials.gov
What's tested:Aminohippurate Sodium Inj 20%Iohexol Inj 300 MG/MLDextran 40

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Effective renal plasma flow (ERPF)
Measured over 3 Hours
+1 more outcome measured
Type 2 Diabetes Mellitus
Diabetic Kidney Disease
Adolescent Obesity
Pre Diabetes
Kidney Hypoxia
Puberty
2 sites across 2 states
Colorado1
Washington1
  • Petter Bjornstad, MD · PRINCIPAL_INVESTIGATOR · University of Washington - Medicine Diabetes Institute

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

HbA1c ≥6.0% for untreated high-risk group
BMI ≥ 85th %ile for high-risk group
Normal HbA1c ≤5.6% for control group
Type 1 diabetes (T1D) Antibody negative

Exclusion

History of Chronic kidney disease (CKD) or acute kidney injury (AKI)
Metabolic disorder prohibiting safe fasting
Iodine or penicillin allergy
Pregnancy
Thrombophilia
MRI contraindications
Hormone therapy
  • Effective renal plasma flow (ERPF)3 Hours

    Measured by PAH Clearance

  • Glomerular Filtration Rate (GFR)3 hours

    Measured by iohexol clearance